With a robust background in technology and healthcare sectors, the fund manager has executed over 30 deals across North America and Europe. Emphasizing a data-driven investment strategy, they have successfully navigated early-stage opportunities while achieving notable exits, including a high-profile sale in the biotech space. Their operator-first approach allows for deep engagement with portfolio companies, ensuring alignment with market trends and innovation. This focus on thematic investments underlines their commitment to identifying disruptive potential in emerging industries.